A20 as a Potential Therapeutic Target for COVID‐19
ABSTRACT Background Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID‐19 may exhibit immunosuppre...
Saved in:
Main Authors: | Yongyao Wu, Lilan He, Rong Li, Jiuxuan Li, Qing Zhao, Bin Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.70127 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress of CCL20-CCR6 in the airways: a promising new therapeutic target
by: Ya -Jing Li, et al.
Published: (2024-12-01) -
Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine
by: Sylvain Lamure, et al.
Published: (2025-01-01) -
The role of the STING inflammatory pathway in hepatic damage in psoriasis with type 2 diabetes mellitus
by: Shulin Huang, et al.
Published: (2024-10-01) -
Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases
by: O. B. Schukina, et al.
Published: (2013-05-01) -
Efficacy of low-dose rituximab versus immunosuppressants in refractory orbital inflammatory pseudotumors with intracranial extension
by: Yuyu Li, et al.
Published: (2025-01-01)